Warning letter
National Biological Corp: warning letter of Jul 11, 2017
FDA warning letter 523732 · New England District Office
Key facts
| Reference number | 523732 |
|---|---|
| Company | National Biological Corp |
| Subject | CGMP/QSR/Medical Devices/Adulterated |
| Issue date | Jul 11, 2017 |
| Posted date | Jul 18, 2017 |
| Issuing office | New England District Office |
| Product type | Devices |
| CFR sections cited | 806, 806.10, 806.2(k), 820 |
| Inspection city | Beachwood |
| Inspection ZIP | 44122 |
| Inspection start date | Mar 6, 2017 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: